secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001581280-25-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience FY2025 revenue $376.6M (+20% YoY); guides for adjusted EBITDA breakeven in Q4 FY2026
--------------------------------------------------------------------------------

- Record FY2025 revenue $376.6M (+20% YoY); Q4 revenue $99.0M (+17% YoY), 11th consecutive sequential growth.
- FY25 gross margin 50.7% vs 42.6% in FY24; Q4 gross margin 51.3% vs 45.1%.
- NGS segment revenue grew 23% to $208.1M; SynBio grew 17% to $145.0M; Biopharma grew 15% to $23.5M.
- Net loss narrowed to $77.7M ($1.30/share) from $208.7M ($3.60/share); adjusted EBITDA -$46.9M vs -$93.5M.
- FY2026 guidance: maintain gross margin >50%; target adjusted EBITDA breakeven by Q4 FY2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000158128025000020/0001581280-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000158128025000020/twist-20251114.htm
  HTML page:      https://secwatch.observer/filing/0001581280-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer